Megan McSweeney

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Here are highlights from this week in Psychiatric Times, including FDA approvals and trial updates.

A new study suggests some people have genetic predispositions for psychiatric conditions that may influence their risk of divorce.

Learn more about the latest research on different approaches to treatments for major depressive disorder (MDD).

Join us in congratulating Dr Tasman on his recent win of the Hartford HealthCare Institute of Living’s 2024 C. Charles Burlingame, MD, award.

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

Researchers investigated the link between psychosis, criminal sanctions, and mortality rates following discharge from a hospital for acute psychosis.

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.

Catch up on coverage from the 63rd Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona.

As the Terminally Ill Adults Bill moves through parliament, government representatives and doctors alike consider the effects legalization may have on patients of psychiatrists.

Looking to buy books as gifts this year? We've got you covered.

Recent research finds that after ECT, pro-inflammatory cytokines decreased significantly, and anti-inflammatory cytokines increased in teenagers with depression.

In a new study, researchers found the subtype of childhood trauma impacts the effectiveness of antipsychotic medications.